Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $370.00, for a total transaction of $370,000.00. Following the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at $4,189,510. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of Regeneron Pharmaceuticals stock opened at $368.81 on Wednesday. Regeneron Pharmaceuticals Inc has a fifty-two week low of $271.37 and a fifty-two week high of $442.00. The business’s fifty day moving average is $331.72 and its two-hundred day moving average is $307.22. The company has a quick ratio of 3.27, a current ratio of 4.03 and a debt-to-equity ratio of 0.07. The firm has a market cap of $40.49 billion, a PE ratio of 18.63, a P/E/G ratio of 1.62 and a beta of 1.19.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, beating the Zacks’ consensus estimate of $5.13 by $1.54. The business had revenue of $2.05 billion during the quarter, compared to the consensus estimate of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.87 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.62 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of REGN. Bank of Nova Scotia boosted its position in shares of Regeneron Pharmaceuticals by 25.4% in the second quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock worth $6,833,000 after acquiring an additional 4,420 shares during the last quarter. KBC Group NV raised its position in shares of Regeneron Pharmaceuticals by 25.6% in the 2nd quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock worth $15,221,000 after buying an additional 9,912 shares during the period. Calamos Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock worth $3,728,000 after buying an additional 248 shares during the period. Gargoyle Investment Advisor L.L.C. boosted its holdings in Regeneron Pharmaceuticals by 6.8% in the second quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock valued at $478,000 after acquiring an additional 97 shares during the last quarter. Finally, Alberta Investment Management Corp boosted its holdings in Regeneron Pharmaceuticals by 8.4% in the third quarter. Alberta Investment Management Corp now owns 22,000 shares of the biopharmaceutical company’s stock valued at $6,103,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors own 66.48% of the company’s stock.
A number of equities research analysts recently issued reports on REGN shares. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Monday, November 11th. Canaccord Genuity lowered their target price on Regeneron Pharmaceuticals from $353.00 to $320.00 and set a “hold” rating on the stock in a report on Wednesday, October 9th. Citigroup raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $340.00 to $420.00 in a research report on Wednesday, November 6th. Robert W. Baird raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a report on Wednesday, August 7th. Finally, SunTrust Banks initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, November 12th. They issued a “hold” rating and a $360.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $384.74.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: Put Option
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.